4h
Hosted on MSNStem Cell Stocks: 10 Biggest NASDAQ Companies in 2025Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...
Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...
Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug ...
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...
An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.
Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous ...
Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results